Hohnloser S H, Klingenheben T, Zabel M, Just H
Department of Cardiology, University Hospital, Freiburg, Germany.
Am J Cardiol. 1993 Aug 12;72(4):67A-71A. doi: 10.1016/0002-9149(93)90027-a.
Reduced vagal activity has been demonstrated to be associated with an increased risk of sudden death. Assessing the heart rate variability as a measure of the autonomic control of the heart has been established as a useful tool for the risk stratification of patients after myocardial infarction. In the current study, heart rate variability assessed by time- and frequency-domain measures was determined from Holter recordings before and during treatment with sotalol in 28 patients with chronic ventricular arrhythmias. The heart rate variability at baseline was independent of the presence or absence of spontaneous arrhythmias and of left ventricular function. Therapy with sotalol produced a significant improvement over control values in indices of parasympathetic tone (root mean square of the difference in successive RR intervals, proportion of adjacent RR intervals different by > 50 msec, high-frequency power spectrum). This improvement was not related to drug-induced changes in the mean heart rate or the suppression of ventricular ectopic activity. These effects on heart rate variability may contribute significantly to the overall efficacy profile of sotalol.
迷走神经活动减弱已被证明与猝死风险增加有关。评估心率变异性作为心脏自主控制的一种测量方法,已被确立为心肌梗死后患者风险分层的有用工具。在本研究中,通过时域和频域测量评估的心率变异性是从28例慢性室性心律失常患者服用索他洛尔治疗前和治疗期间的动态心电图记录中确定的。基线时的心率变异性与是否存在自发性心律失常及左心室功能无关。索他洛尔治疗使副交感神经张力指标(连续RR间期差值的均方根、相邻RR间期相差>50毫秒的比例、高频功率谱)较对照值有显著改善。这种改善与药物引起的平均心率变化或室性异位活动的抑制无关。这些对心率变异性的影响可能对索他洛尔的整体疗效有显著贡献。